I’ve been recommending ACADIA for years, first jumping in around $20 a share.
Today, on news the FDA granted priority review, it’s up $5 on the day. But upside is far from over. In fact, what this company is offering is a game changer for the Parkinson’s disease Psychosis (PDP) community where no treatment exists.
When — and – if it’s approved, millions of sufferers may have relief from the issue characterized by wild hallucinations and delusions.
It’s another step closer to FDA approval… and helping meet an unmet medical need. Even after today’s run to $40.25, it’s still a buy. Consider buying the underlying stock up to $43.
Ian L. Cooper
Rapid Retirement System